Friday, October 05, 2018 9:04:09 PM
Around $1: We get a B deal with a mid-tier pharma and get some expensive financing for P results, and those results are "good" (efficacy, but not strong). No BTD for B-OM.
BTD: Add $.50
Cheaper financing: Add $.25. $.50 if a strategic investment by the pharma, or if it's a BP (top tier).
Strong P results: Add $1.
But I also remind them that nothing is sure here, including news. The chance of a deal is really good. We've got a term sheet, we need a deal badly, and our management is not stupid. P is a huge wild card, and its efficacy is not a sure bet. The Phase 2A had tantalizing signs, that's all. More of the drug may not have more of an effect. That's just not the given nature of pharmaceuticals unfortunately. We have to see. B-OM BTD is possible, but the FDA can disappoint. They may have serious doubts from the Phase 2 arm that didn't show any improvement and decide that just OK'ing a Phase 3 is appropriate.
Biotech...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM